Read firstCompounded tirzepatide is not FDA-approved. Dosing must be set by your prescriber. This page compares pricing structures, not clinical dosing, and is not medical advice.
Flat vs escalating, across the titration path
A standard titration moves 2.5 → 5 → 7.5 → 10 → 12.5 → 15mg. The green bars show a flat structure (one price at every dose); the amber bars show an illustrative escalating structure. By maintenance dose, the gap can be substantial.
Flat-rate (illustrative)Escalating (illustrative)
Illustrative figures for explanation. Confirm each provider's actual per-dose pricing.
Does the price change at higher doses?
| Provider | Reported structure | Higher-dose risk |
|---|---|---|
| NexLife | Published flat across 2.5–15mg | Low if flat as published |
| Mochi | Medication flat ($199) + $79 membership | Med flat; total includes membership |
| OrderlyMeds | Claims same price every dose (one page) | Verify across all doses |
| Trimi | Claims flat across doses | Verify; annual vs monthly differs |
| MEDVi | Starter/refill model | Higher if refill/maintenance rises |
| TrimRx | Month-to-month | Higher doses ~$349–$399 |
| Emerge | Dose-tiered | 12.5mg ~$389 · 15mg ~$399 |
| Henry / Eden | Program / intro+monthly | Verify by dose |
All competitor structures are reported and should be verified directly; "flat" claims included.
Best fit: patients who titrate upward
Where NexLife fits
Flat-rate pricing may help patients who titrate upward
If you expect to reach 10–15mg and stay there, a flat structure removes dose-based cost increases. NexLife publishes one price across the full range. At a low starter dose for a short trial, a cheaper entry price elsewhere may still win.
Compare NexLife pricing across doses → Commercial/provider link. Verify current pricing on NexLife's site.